CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹61 Cr | ₹-31 Cr | ₹82 Cr | ₹184 Cr | ₹622 Cr |
What is the latest Total Non-Current Liabilities ratio of CIPLA ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹61 Cr |
| Mar2025 | ₹-31 Cr |
| Mar2024 | ₹82 Cr |
| Mar2023 | ₹184 Cr |
| Mar2022 | ₹622 Cr |
How is Total Non-Current Liabilities of CIPLA Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹61 Cr | Positive | |
| Mar2025 | ₹-31 Cr | Negative | |
| Mar2024 | ₹82 Cr | -55.36 | |
| Mar2023 | ₹184 Cr | -70.48 | |
| Mar2022 | ₹622 Cr | - | |
Compare Total Non-Current Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹113,784.6 Cr | -2% | -2.5% | -8.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,114.0 Cr | NA | -3.9% | 17.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹239,321.0 Cr | 5% | 21.5% | 44.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹185,924.0 Cr | -2.1% | -0.2% | 34.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,025.9 Cr | 0.4% | 4.5% | -4.4% | Stock Analytics | |
| MANKIND PHARMA | ₹98,829.9 Cr | 0.3% | -8.6% | -5.5% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -2% |
-2.5% |
-8.1% |
| SENSEX | 0.7% |
0.8% |
-5.1% |
You may also like the below Video Courses